Research Paper

Serum Anti-heat Shock Protein 27 Antibody Titers in Patients With Dyslipidemia: A Population-based Case-control Study

Fatemeh Sadabadi1,2*, Maryam Shahi3*, Sousan Darroudi1,2, Azam Rastgar Moghadam2, Sahar Heidari-Bakavoli7, Asma Porsa1, Sara Safar Soflaei7, Habibollah Esmaeili7, Mohsen Mouhebati7, Ghodratollah Salehi Sangani7, Gordon Ferns9, Bibi Razieh Hoseini Farash8, Majid Ghayour-Mobarhan2,4**

1. Cutaneous Leishmaniasis Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
2. Metabolic Syndrome Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
3. Blood Borne Infections Research Center, Academic Center for Education, Culture and Research, Razavi Khorasan Branch, Mashhad, Iran.
4. Department of Nutrition, International UNESCO Center for Health-related Basic Sciences and Human Nutrition, Mashhad University of Medical Sciences, Mashhad, Iran.
5. Department of Biology, School of Sciences, Ferdowsi University of Mashhad, Mashhad, Iran.
6. Department of Biostatistics & Epidemiology, Management & Social Determinants of Health Research Center, School of Health, Mashhad University of Medical Sciences, Mashhad, Iran.
7. Cardiovascular Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
8. Department of Parastidology and Mycology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
9. Department of Medical Education, School of Brighton & Sussex Medical, Brighton, UK.

*Equally contributed as first authors

** Corresponding Author:
Majid Ghayour-Mobarhan, MD, PhD.
Address: Metabolic Syndrome Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Phone: (+98) (511) 8002287
E-mail: ghayourm@mums.ac.ir

Background: Heat shock protein 27 (HSP27) is found in several cell types of adults, such as cardiomyocytes, and endothelial cells. It is expressed in response to different cellular stress conditions. HSP27 decreases the levels of reactive oxygen species (ROS) and dyslipidemia is closely associated with increased endothelial production of reactive oxygen species (ROS).

Objective: Higher serum HSP27 antigen and anti-HSP27 antibodies have been reported in patients with unstable angina and myocardial infarction.

Methods: This population-based case-control study was conducted in 2018. We investigated serum anti-HSP27 antibody titers in all participants with dyslipidemia from the Mashhad stroke and heart atherosclerotic disorder (MASHAD) study (n=8141) and those who were healthy in terms of dyslipidemia (n=1637) using an in-house enzyme-linked immune sorbent assay (ELISA) in individuals with dyslipidemia.

Findings: Anti-HSP27 titers were significantly lower in individuals with dyslipidemia compared to people without dyslipidemia (P=0.036).

Conclusion: Our results revealed that the anti-HSP27 antibody titer was lower in the participants with dyslipidemia than in the negative group. However, there may be a confounding effect of drug therapy. In a subgroup of dyslipidemic subjects, we observed lower anti-HSP27 antibody titers in patients treated with some drugs (statins or corticosteroids, non-steroidal anti-inflammatory drugs [NSAIDs], or anti-diabetic and anti-hypertensive) compared to subjects untreated with these drugs.
1. Introduction

Dyslipidemia has long been recognized as a risk factor for cardiovascular disease [1], and atherogenic dyslipidemia may increase metabolic risk [2, 3]. The main features of dyslipidemia are defined by hypertriglycerideremia, low level of high-density lipoprotein cholesterol (HDL-C), and elevated or normal level of low-density lipoprotein cholesterol (LDL-C) [4]. We defined dyslipidemia as increased triglyceride (TG≥150 mg/dL) and or increased LDL-C (LDL-C≥130 mg/dL), and or decreased HDL-C (HDL-C≤40 mg/dL) in men and (HDL-C≤50 mg/dL) in women [5].

Several HSPs protect cells against stress, such as UV light and oxidative stress. Heat shock protein 27 (HSP27) decreases the levels of reactive oxygen species (ROS) [6-10]. On the other hand, dyslipidemia is closely associated with increased endothelial production of reactive oxygen species (ROS) [1].

Various pathological conditions, such as dyslipidemia are categorized by the deficiency of heat shock response, which plays a key role in the onset or worsening of the disease [11-13]. HSP27 is expressed in response to different cellular stress conditions. HSP27 is found in several cell types of adults, such as breasts, uterus, platelets, cardiomyocytes, and endothelial cells [14, 15].

It has been reported that HSP27 expression is lower in atherosclerotic plaques compared to control arteries, and therefore it was proposed that reduced HSP27 expression may be related to the plaque complexity [16]. However, Park et al. have reported that serum levels of HSP27 are higher in patients with acute coronary syndrome compared to healthy controls; nevertheless, they found that the level of HSP27 was undetectable in the core of atherosclerotic plaques [17]. Serum antibody titers against this protein (anti-HSP27) have been reported in a small number of studies. Higher serum HSP27 antigen and anti-HSP27 antibodies have been reported in patients with unstable angina and myocardial infarction [18]. It has been found that increased antibody titers against HSP27 are related to increased cardiovascular morbidity and mortality [19]. In our previous study, we found high serum anti-HSP27 titers in individuals with high fasting serum triglycerides and low HDL-C [20].

However, serum anti-HSP27 has not been fully explored in dyslipidemic patients. In this study, we evaluated serum levels of anti-HSP27 antibody in dyslipidemic subjects recruited into the Mashhad stroke and heart atherosclerotic disorder (MASHAD) Study cohort.

2. Material and Methods

In the present study, all samples were obtained from individuals recruited to the MASHAD study population. The MASHAD study, one of the first cohorts of cardiovascular disease (CVD) in the Middle East, aimed to assess the influence of environmental, nutritional, psychosocial, and genetic risk factors on the prevalence of cardiovascular events started in 2007. Participants aged 35-65 years were selected from the urban population of Mashhad City, the northeastern region of Iran. This research has been approved by the Ethics Committee of Mashhad University of Medical Sciences. All individuals included in this study signed written consent. In the present research, all participants with dyslipidemia from the MASHAD study (n=8141) and healthy people in terms of dyslipidemia (n=1637) were investigated. The seven different dyslipidemic statuses studied in this study are as follows:

- TG↑, HDL-C↓, LDL-C↑,
- TG↑ & HDL-C↓, TG↑ & LDL-C↑,
- TG↑ & HDL-C ↓ & LDL-C ↑,
- HDL-C↓ & LDL-C ↑.

Individuals who suffered from cardiovascular disease before entering the study or were pregnant or breastfeeding women were excluded from the study.

Initially, blood samples were collected from volunteers after a 12- hour fasting. The assessment of anthropometric, demographic, and biochemical parameters is described in detail previously [21]. Biochemical tests were performed on serum samples using commercial kits by an Alcyon analyzer (ABBOTT, Chicago, IL, USA).

The serum HSP27 antibody levels were assessed using an in-house enzyme-linked immune sorbent assay (ELISA), as previously described [20].

Statistical analysis

All statistical analyses were performed using SPSS software, version 18. The variable with normal and non-normal distribution was shown as Mean±SD and median and interquartile range respectively. All groups were compared using analysis of variance (ANOVA) and Kruskal-Wallis tests with a Bonferroni correction.
Multivariate regression analyses were performed to evaluate the independent effects of age, gender, smoking, and drug use on anti-HSP27 levels in patients with dyslipidemia. Data about taking drugs was collected using a questionnaire. The level of statistical significance was set at P<0.05.

3. Results

Baseline biochemical, anthropometric, and demographic characteristics in dyslipidemic and non-dyslipidemic participants

This study was conducted on 9759 patients. Approximately 40% of them were men and 60% were women.

Table 1. Comparison of the baseline biochemical, anthropometric and demographic characteristics of participant with or without dyslipidemia

| Variables                     | Dyslipidemia+(n=8141) | Dyslipidemia-(n=1637) | P      |
|-------------------------------|-----------------------|-----------------------|--------|
| Age (y)                       | 48.22±8.19            | 47.30±8.55            | <0.001 |
| Height (m)                    | 1.60±0.09             | 1.62±0.09             | <0.001 |
| Weight (kg)                   | 72.55±12.81           | 67.92±12.47           | <0.001 |
| Waist circumference (cm)      | 96.4±11.84            | 91.19±12.15           | <0.001 |
| Hip circumference (cm)        | 104.22±9.26           | 101.28±9.29           | <0.001 |
| BMI (kg/m²)                   | 28.28±4.65            | 25.96±4.68            | <0.001 |
| Systolic blood pressure (mm Hg)| 122.11±18.81          | 120.37±20.48          | 0.002  |
| Diastolic blood pressure (mm Hg)| 79.34±11.96          | 78.18±10.82           | <0.001 |
| Triglycerides (mg/dL)         | 131 (93-184)a         | 83 (63-108)a          | <0.001 |
| Cholesterol (mg/dL)           | 194.61±40.81          | 175.18±23.49          | <0.001 |
| HDL-C (mg/dL)                 | 40.78±8.77            | 53.12±8.95            | <0.001 |
| LDL-C (mg/dL)                 | 120.10±36.47          | 99.09±21.10           | <0.001 |
| FBG (mg/dL)                   | 94.02±41.09           | 86.04±28.15           | <0.001 |
| Hs-CRP (mg/dL)                | 1.7 (1.02-3.66)a      | 1.33 (0.89-2.81)a     | 0.07   |
| Gender                        |                       |                       |        |
| Male                          | 37.6 (3057)           | 52.1 (848)            | <0.001 |
| Female                        | 62.4 (5073)           | 47.9 (781)            |        |
| Smoking                       |                       |                       |        |
| Never                         | 58.4                  | 69.3                  |        |
| Past                          | 9.8                   | 10.4                  | 0.384  |
| Current                       | 21.7                  | 20.3                  |        |
| Diabetes                      | 15.3                  | 8.7                   | <0.001 |
| Hypertension                  | 32.7                  | 26.1                  | <0.001 |
| Anti-HSP27 (OD)               | 0.208 (0.105-0.345)a  | 0.213 (0.113-0.356)a  | 0.036  |

BMI: Body mass index; FBG: Fasting blood glucose; LDL-C: Low-density lipoprotein cholesterol; HDL-C: High-density lipoprotein cholesterol; Hs-CRP: High sensitivity C-reactive protein; OD: Optical density; HSP: Heat shock protein; Median (interquartile range) due to skewed distribution.
Table 1 presents the baseline biochemical, anthropometric, and demographic characteristics of participants. All parameters showed a significant difference in individuals with dyslipidemia and subjects without dyslipidemia, except for smoking and high-sensitivity C-reactive protein (Hs-CRP). In the dyslipidemic group, the rates of hypertension (32.7%) and diabetes mellitus (15.3%) were significantly higher than those without dyslipidemia (P<0.001). Age, weight, waist circumference, hip circumference, Body Mass Index (BMI), systolic and diastolic blood pressure, TG, Cholesterol, LDL-C, and Glucose were also significantly higher in the dyslipidemic group compared to participants without dyslipidemia (P<0.002 for systolic blood pressure and P<0.001 for other parameters).

Anti-HSP27 levels were significantly lower in participants with dyslipidemia compared to those without dyslipidemia (P=0.036; Table 1).

| Variable          | Normal (n: 1689) | TG↑ (n: 404) | HDL-C ↓ (n: 2840) | LDL-C ↑ (n: 913) | P    |
|-------------------|------------------|--------------|-------------------|------------------|------|
| Anti-HSP27 (OD)   | 0.213 (0.112-0.357) | 0.219 (0.109-0.361) | 0.208 (0.104-0.348) | 0.190 (0.108-0.334) | 0.114 |

HSP: Heat shock protein; LDL-C: Low-density lipoprotein cholesterol; HDL-C: High-density lipoprotein cholesterol; OD: Optical density.

Data are presented as the median and interquartile range for non-normally distributed data and differences in variables among study groups assessed using the Kruskal-Wallis H test.

The comparison of the serum anti-HSP27 antibody titers in dyslipidemic patients suffering from high TG or only low HDL-C or high LDL-C (individuals with two or three characteristics were not dyslipidemia) with healthy subjects was reviewed and no significant difference was observed (Table 2).

Serum anti-HSP27 antibody titers in three dyslipidemic statuses of dyslipidemia (TG↑, HDL-C↓, LDL-C↑) and healthy subjects were compared between males and females, and no significant differences were observed between the two genders were detected (Figure 1).

A comparison of serum anti-HSP27 antibody titers was evaluated among different combined dyslipidemia status and normal participants and no significant differences were seen between the groups (Table 3).

The levels of serum anti-HSP27 antibodies were compared between men and women in patients with combined dyslipidemia and normal subjects were compared, but no significant difference was observed between the groups (Table 4).

Figure 1. Comparison of serum anti-heat shock protein (HSP27) antibody titers between males and females in 2 groups of dyslipidemia and healthy
Multivariate regression analysis of anti-heat shock protein (HSP27) in participants with dyslipidemia

Different multivariate regression models were conducted to assess the effect of age, gender, smoking, and drug use on anti-HSP27 levels in participants with dyslipidemia (Table 5).

Dyslipidemia was regarded as a dependent factor and anti-HSP27 as a covariate in model 1. Model 1 showed that people with a higher level of anti-HSP27 had a 68% lower risk of dyslipidemia ($P=0.022$). Also, in model 2 (age and gender were adjusted) and in model 3 (age, gender, and cigarette smoking were adjusted). In model 4, age, gender, cigarette smoking, and drug use (corticosteroids, non-steroidal anti-inflammatory drugs [NSAIDs], and statins) were adjusted. In model 4, the relationship between anti-HSP27 level and dyslipidemia was not significant.

4. Discussion

In the present study, anti-HSP27 levels were found to be significantly lower in participants with dyslipidemia compared to those without dyslipidemia ($P=0.036$).

HSP and anti-HSP immune complexes can lead to the destabilization of atherosclerotic plaque. Activation of the complement system may be an imperative factor in the chronic inflammatory process associated with atherosclerosis. The particular role of anti-HSP immunity in vascular disease is controversial [22]. Several studies have shown that higher levels of CVD risk factors are directly related to higher levels of anti-HSP antibodies and have concluded that anti-HSP antibodies may have a pathologic role in atherosclerosis. Anti-HSP27 antibody levels are related to cardio/cerebrovascular events [23, 24]. Since HSP27 has a vital role in myocardial protection in CVD [13], maybe the presence and increasing the anti-HSP27 level causes the formation of HSP and anti-HSP immune complexes and reduces the protective effect of HSP in patients with cardiovascular disease.

Table 4. Comparison of serum anti-Heat Shock Protein (HSP27) antibody titers between males and females in patients with combined dyslipidemia and normal subjects

| Sub-Groups                          | Anti-HSP27 (OD) | P    |
|-------------------------------------|----------------|------|
|                                     | Male           | Female |      |
| Normal (Male:836, female:765)       | 0.197 (0.115-0.354) | 0.220 (0.109-0.354) | 0.98 |
| TG↑ & HDL-C ↓ (Male:723, female:942) | 0.208 (0.105-0.340) | 0.206 (0.102-0.336) | 0.53 |
| TG↑ & HDL-C ↓ and LDL-C ↑ (Male:280, female:599) | 0.210 (0.108-0.336) | 0.197 (0.097-0.331) | 0.66 |
| HDL-C↓ and LDL-C ↑ (Male:266, female:789) | 0.235 (0.107-0.426) | 0.220 (0.110-0.337) | 0.11 |
| TG↑ & LDL-C ↑ (Male:209, female:169) | 0.178 (0.088-0.311) | 0.193 (0.086-0.350) | 0.66 |

HSP: Heat shock protein; LDL-C: Low-density lipoprotein cholesterol; HDL-C: High-density lipoprotein cholesterol; OD: Optical density. Data are presented as the median and interquartile range for non-normally distributed data and differences in variables among study groups assessed using the Kruskal-Wallis H test.
In the previous study, we conducted for acute coronary syndrome in our lab, it was revealed that anti-HSP27 increased in the first 12 hours but decreased in the next 12 hours. This finding was concluded to suggest that the formation of immune complexes between anti-HSP27 and HSP27 antigens rapidly clears this complex via Fc-receptor [25].

Pourghadamyari et al. contrary to our results showed that CAD+ patients had significantly higher anti-HSP27 titers compared to both CAD− and control groups [26].

In another study on CAD patients, consistent with our results, lower levels of serum anti-HSP27 and HSP27 were observed in the CAD group compared to the healthy control, and after 6 months, this result did not change [27].

In contrast to our finding, Azarpazhooh et al. found that the serum level of anti-HSP27 antibodies of patients with stroke was significantly higher than the control group in the first 24 hours after the onset of stroke [28].

In contrast to our findings, Shams et al. found a higher level of anti-HSP27 in patients with chest pain both at admission time and 12 hours later compared to healthy control. According to the Shams and the results of our study, patients with acute cardiac chest pain with hypertension and hyperlipidemia had lower anti-HSP27 IgG antibody levels than patients without hypertension and hyperlipidemia [29]. Maybe the level of anti-HSP27 in people with dyslipidemia is different from other diseases, furthermore using some drugs affects the anti-HSP27 antibody titer in patients with dyslipidemia.

5. Conclusion

In multivariate regression that adjusted age, gender, and smoking, no effect was observed on anti-HSP27 in dyslipidemic patients. However, when taking statins, corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), and anti-diabetic and anti-hypertensive drugs were adjusted for this test, the relationship between anti-HSP27 level and dyslipidemia was not significant. These results showed that using these drugs can affect the level of anti-HSP27 antibodies in dyslipidemic patients. In our previous study, we showed that statin therapy in dyslipidemic subjects can reduce heat shock protein antibody titers and concluded that reduction in HSP antibody titers following statin treatment may be related to the other immunomodulatory properties of this class of drugs [30].

We concluded that maybe using different drugs in dyslipidemic patients reduced the level of anti-HSP27 in dyslipidemic patients compared to subjects without dyslipidemia. The next study could be to follow anti-HSP27 levels in dyslipidemic patients with cardiovascular disease at the admission time and 12 hours later compared to patients without cardiovascular disease.

Ethical Considerations

Compliance with ethical guidelines

This research was approved by the Ethics Committee of Mashhad University of Medical Sciences by the Declaration of Helsinki (Code: IR.MUMS.REC.1386.250). Informed consent was obtained from all individuals recruited for the study.

Table 5. Different model of multivariate regression for anti-heat shock protein (HSP27) and dyslipidemia

| Models       | OR (CI 95%) | P  |
|--------------|------------|----|
| Model 1      | 0.68 (0.49-0.95) | 0.022 |
| Anti-HSP27 (OD) | 0.71 (0.51-0.99) | 0.044 |
| Model 3      | 0.68 (0.51-0.99) | 0.049 |
| Model 4      | 0.72 (0.52-1)   | 0.055 |

Model 1, unadjusted; Model 2, adjusted for age, and gender; Model 3, adjusted for age, gender and smoking; Model 4, adjusted for age, gender, smoking, and using the drug.

HSP: Heat shock protein; OD: Optical density; CI: Confidence interval.
Funding

This paper was extracted from the thesis of the first author and supported by the Mashhad University of Medical Sciences.

Authors’ contributions

Conceptualization, methodology, software, and, writing–review & editing: Fatemeh Sadabadi, Maryam Shahi, and Sousan Darroudi; Measurement of anti-HSP27 antibody: Azam Rastgar Moghadam, Sahar Heidari-Bakavoli, and Asma Porsa; Data analysis: Sara Saflar Soflaei and Habibollah Esmaeili; Supervision: Mohsen Mouhebati. Visualization and investigation, resources: Ghodratollah Salehi Sangani, and Bibi Razieh Hoseini barhan; All authors reviewed the manuscript.

Conflict of interest

The authors declared no conflict of interest.

Acknowledgments

We thank the Deputy of Research, Mashhad University of Medical Sciences for support.

References

[1] Gijsberts CM, Seneviratna A, de Carvalho LP, den Ruijter HM, Vidanapthirana P, Sorokin V, et al. Ethnicity modifies associations between cardiovascular risk factors and disease severity in parallel Dutch and Singapore coronary cohorts. PloS One. 2015; 10(7):e0132278. [DOI:10.1371/journal.pone.0132278] [PMID] [PMCID]

[2] Chen CY, Lee CW, Chien SC, Su MI, Lin SI, Cheng CW, Hung TC, Yeh HI. Dyslipidemia management for elderly people with metabolic syndrome: a mini-review. International Journal of Gerontology. 2018; 12(1):7-11. https://www.sciencedirect.com/science/article/pii/S1873959817300054

[3] Sadabadi F, Heidari-Bakavoli A, Esmaily H, Darroudi S, Tayefi M, Asadi Z, et al. Is there any association between Serum anti-HSP27 antibody level and the presence of metabolic syndrome: population based case-control study. Rev. Romana de Medicina de Lab. 2019; 27(2):179-87. [DOI:10.2478/rmlm-2019-0016]

[4] Tangvarasittichai S. Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus. WJD. 2015; 6(3):456. [DOI:10.4239/wjd.v6i3.456] [PMID] [PMCID]

[5] Ghayour-Mobarhan M, Moohebati M, Esmaeily H, Ebrahimi M, Parizadeh SM, Heidari-Bakavoli AR, Safarian M, Mokhber N, Nematy M, Saber H, Mohammadi M. Mashhad stroke and heart atherosclerotic disorder (MASHAD) study: design, baseline characteristics and 10-year cardiovascular risk estimation. Int J Public Health. 2015; 60(5):561-72. [Link]

[6] Vidyasagar A, Wilson NA, Djamali A. Heat shock protein 27 (HSP27): biomarker of disease and therapeutic target. Fibrogenesis Tissue Repair. 2012; 5(1):1-7. [DOI:10.1186/1755-1356-5-7] [PMID] [PMCID]

[7] Li Z, Srivastava P. Heat-shock proteins. Curr Protoc Immunol. 2004; 1(10):A-1T. [DOI:10.1002/0471142735.im-a01ts58] [PMID]

[8] Whitley D, Goldberg SP, Jordan WD. Heat shock proteins: A review of the molecular chaperones. J Vasc Surg. 1999; 29(4):748-51. [DOI:10.1016/S0741-5214(99)70392-0]

[9] Rizzo M, Cappello F, Marfili R, Nibali L, Gammassa AM, Rappa F, et al. Heat-shock protein 60 kDa and atherogenic dyslipidemia in patients with untreated mild periodontitis: a pilot study. Cell Stress Chaperones. 2012; 17(3):399-407. [DOI:10.1007/s12192-011-0315-1] [PMID] [PMCID]

[10] Naik P. Biochemistry: JP Medical Ltd; 2015. [Link]

[11] Padmalyam I. The heat shock response: its role in pathogenesis of type 2 diabetes and its complications, and implications for therapeutic intervention. Discov Med. 2014; 18(97):29-39. [Link]

[12] Tian M, Zhu L, Lin H, Lin Q, Huang P, Yu X, Jing Y. Hsp-27 levels and thrombus burden relate to clinical outcomes in patients with ST-segment elevation myocardial infarction. Oncotarget. 2017; 8(43):73733. [DOI:10.18632/oncotarget.17852] [PMID] [PMCID]

[13] Wu J, Jiang S, Ding Z, Liu L. Role of heat shock protein 27 in cardiovascular disease. J Biochem Pharmacol Res. 2013; 1:43-50. [Link]

[14] Ciocca DR, Oesterreich S, Channess GC, McGuire WL, Fuqua SAW. Biological and Clinical Implications of Heat Shock Protein 27000 (HSP27): a Review. JNCI. 1993; 85(19):1558-70. [DOI:10.1093/jnci/85.19.1558] [PMID]

[15] Tavana M, Ghazizadeh H, Sadeghzade M, Tavalaie S, Abolbashari S, Ramshini H, Ghayour_Mobarhan M, Sadabadi F. Serum anti-HSP27 antibodies concentration in diabetes mellitus; population based case-control study. Med Lab Sci. 2019; 5(1):12-7. https://scholar.google.com/scholar?hl=en&as_sdt=0%2C5&q=Serum+antiHSP27+antibodies+c...[PMID]

[16] Martin-Ventura JL, Duran MC, Blanco-Colio LM, Meilhac O, Leclercq A, Michel J-B, et al. Identification by a differential proteomic approach of heat shock protein 27 as a potential marker of atherosclerosis. Circulation. 2004; 110(15):2216-9. [DOI:10.1161/01.CIR.0000136814.87170.B1] [PMID]

[17] Park HK, Park E-C, Bae SW, Park MY, Kim SW, Yoo HS, et al. Expression of heat shock protein 27 in human atherosclerotic plaques and increased plasma level of heat shock protein 27 in patients with acute coronary syndrome. Circulation. 2006; 114(9):886-93. [DOI:10.1161/CIRCULATIONAHA.105.541219] [PMID]
[18] Kargari M, Parizadeh SMR, Karimian MS, Farahmand SK, Sahebkar A, Esmaeili H, et al. Serum anti-HSP27 antibody titers in patients with metabolic syndrome, with or without diabetes mellitus. Comp Clin Path. 2016; 25(4):895-901. [DOI:10.1007/s00580-016-2279-0]

[19] Makowski GS. Advances in clinical chemistry. Houston, Texas: Gulf Professional Publishing; 2005. [Link]

[20] Sahebkar A, Pourghadamyari H, Mohebati M, Parizadeh SMR, Falsouleiman H, Dehghani M, et al. A cross-sectional study of the association between heat shock protein 27 antibody titers, pro-oxidant-antioxidant balance and metabolic syndrome in patients with angiographically-defined coronary artery disease. Clin Biochem. 2011; 44(17):1390-5. [DOI:10.1016/j.clinbiochem.2011.09.011] [PMID]

[21] Ghayour-Mobarhan M, Moohebati M, Emam H, Ebrahimi M, Parizadeh SMR, Heidari-Bakavoli AR, et al. Mashhad Stroke and Heart Atherosclerotic Disorder (MASHAD) study: design, baseline characteristics and 10-year cardiovascular risk estimation. Int J Public Health. 2015; 60(5):561-72. [DOI:10.1007/s00038-015-0679-6] [PMID]

[22] Gromadzka G, Zielinska J, Ryglewicz D, Fiszer U, Czlonkowska A. Elevated levels of anti-heat shock protein antibodies in patients with cerebral ischemia. Cerebrovasc Dis. 2001; 12(3):235-9. [DOI:10.1159/000047709] [PMID]

[23] Tavallaie S, Rahsepar AA, Abdi H, Mohebati M, Moodi F, Pourghadamyari H, et al. Association between indices of body mass and antibody titers to heat-shock protein-27 in healthy subjects. Clinical biochemistry. 2012; 45(1-2):144-7. [DOI:10.1016/j.clinbiochem.2011.09.022] [PMID]

[24] Sadabadi F, Zirak RG, Ghazizadeh H, Moghadam AR, Mouhebati M, Ehyaei S, et al. Physical activity level (PAL) and risk factors of cardiovascular disease in the MASHAD study cohort. Diabetes Metab Syndr: Clin Res Rev. 2021; 15(6):102316. [DOI:10.1016/j.dsx.2021.102316] [PMID]

[25] Ghayour-Mobarhan M, Sahebkar A, Parizadeh SMR, Mohebati M, Tavallaie S, RezaKazemi-Bajestani SM, et al. Antibody titres to heat shock protein 27 are elevated in patients with acute coronary syndrome. Int J Exp Pathol. 2008; 89(3):209-15. [DOI:10.1111/j.1365-2613.2008.00586.x] [PMCID]

[26] Pourghadamyari H, Mohebati M, Parizadeh SMR, Falsouleiman H, Dehghani M, Fazlinezhad A, et al. Serum antibody titers against heat shock protein 27 are associated with the severity of coronary artery disease. Cell Stress Chaperones. 2011; 16(3):309-16. [DOI:10.1007/s12192-010-0241-7] [PMID] [PMCID]

[27] OBrien ER, Shi C, Chen YX, Gwilym B, Massey C, Hellmich A, Gerthoffer W. HSP27 and Anti-HSP27 Autoantibodies: Novel CAD biomarkers that non-invasively stratified a medically underserviced population. Circulation. 2016; 134(suppl_1):A14071. https://www.ahajournals.org/doi/abs/10.1161/circ.134.suppl_1.14071

[28] Azarpazhooh MR, Mobarra N, Parizadeh SMR, Tavallaie S, Bagheri M, Rahsepar AA, et al. Serum high-sensitivity C-reactive protein and heat shock protein 27 antibody titers in patients with stroke and 6-month prognosis. Angiology. 2010; 61(6):607-12. [DOI:10.1177/0003319709360524] [PMID]

[29] Shams S, Shafi S, Bodman-Smith K, Williams P, Mehta S, Ferns GA. Anti-heat shock protein-27 (Hsp-27) antibody levels in patients with chest pain: association with established cardiovascular risk factors. Clinica Chimica Acta. 2008; 395(1):42-6. [DOI:10.1016/j.cca.2008.04.026] [PMID]

[30] Ghayour-Mobarhan M, Lamb D, Vaidya N, Livingstone C, Wang T, Ferns G. Heat shock protein antibody titers are reduced by statin therapy in dyslipidemic subjects: a pilot study. Angiology. 2005; 56(1):61-8. [DOI:10.1177/0003319705060108] [PMID]